Precision Medicine Applied to the Study of Endometrial Cancer: Application of NGS for Molecular Classification

Inclusion criteria

• Patients over 18 years of age with a diagnosis of EC diagnosed by histological biopsy and surgically treated sequentially in the participating centers in the last 5 years with clinical follow-up.
• Patients over 18 years of age, diagnosed with CE III-IV by histological biopsy, not susceptible to surgical treatment in each institution during the last 5 years in clinical follow-up. Cases with a diagnosis of carcinosarcoma (a rare subtype of endometrial carcinoma with sarcomatous transdifferentiation) are included.
• Material blocks fixed in formalin and embedded in paraffin with a tumor volume in the paraffin block of at least 1 cm3

Exclusion criteria

• The following uterine neoplasms will be excluded:

• Biphasic tumors (epithelial-mesenchymal) such as adenosarcoma.
• Mesenchymal neoplasms such as endometrial stromal sarcoma and leiomyosarcomas.
• Others: primary lymphoproliferative processes of the uterine body; neuroendocrine tumors; Gestational trophoblastic disease, secondary lesions either of the genital tract (example: cervical carcinomas with extension to the endometrium) or of distant sites (breast cancer metastasis).

• Patients with synchronous endometrial and ovarian carcinoma
• For technical reasons, they will be excluded
• tumors smaller than 0.2 cm in which sufficient material cannot be obtained for immunohistochemical and molecular biology determinations.
• Tumors with severe artifacts due to poor processing, such as autolysis.
• Samples with low-quality DNA

• Patients operated on outside participating centers.
• Patients under 18 years of age.
• Patients with primary non-surgical treatments (neoadjuvant chemotherapy).